Article
Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy.
Cardiovascular drugs and therapy - 1 Apr 2020
Mazzarotto Francesco, Olivotto Iacopo, Walsh Roddy
Abstract excerpt
As the price of next-generation sequencing keeps decreasing, cost is becoming a less important discriminator for diagnostic laboratories in choosing the preferred type of approach to genetic testing. Genome-wide sequencing strategies will plausibly become the standard first-tier tools for genetic testing, with the potential for deeper understanding of the genetic architecture of cardiomyopathies and discovery of...
Topics
Join the communities discussing this publication.
